

WORLD MARROW
DONOR ASSOCIATION

2020 WMDA Finance & Activities Report

CONTENTS

04

Foreword President

06

2020 at a Glance

08

Strategy

10

Activities

18

World Marrow Donor Day

20

EU Third Health Programme

22

Financial report

25


Work Plan and Budget 2021

26

WMDA Office Hours

27

Board Members 2020



FOREWORD PRESIDENT

Dear WMDA members,

With this WMDA Activities and Finance Report, we invite you to read up on our association's projects, educational activity and overall productivity during 2020. The achievements mentioned in this report illustrate once again that all our efforts aim to contribute to WMDA's vision that patients worldwide have equal access to high-quality cells for transplantation from donors whose rights and safety are protected.

Needless to say, our activities in 2020 were influenced by the ongoing COVID-19 pandemic. Despite the challenges, we have been able to demonstrate a strong commitment to our donors and members by providing guidelines for registries, having operational information readily available, organising a European waiver for transport of cells between EU Member States and transforming the annual face-to-face meeting into a Virtual Meeting. All online information was kept up-to-date to provide valuable and current data on the pandemic and the impact it had on transportation and operations in the various countries where our members reside. More recently, the Donor Suitability Committee produced information on COVID-19 vaccines - also available on WMDA Share.

The pandemic also prevented us from having the International Donor Registry Conference, initially planned to be held in Quebec. Unfortunately, the conference had to be cancelled for both 2020 and 2021. Nonetheless, WMDA was able to hold a virtual meetings week instead of the International Donor Registry Conference. With more than 300 registered attendees from 55 countries, it was an interactive and informative event which showcased the latest developments in stem cell donation and registry operations. Other successful events, all organised online, included the COVID webinars, the 15-minute webinars on Quality & Accreditation, the monthly search coordinator curriculum and the communication webinars. Visit the sections in WMDA Share under Pillar 2 and Pillar 4 for more detailed information and links to all the webinars.

Considering the COVID-19 pandemic, the WMDA's strategic decision to increase the educational activity by developing the E-learning platform, taken back in 2018, was even more relevant and helpful to our members. The platform features many informative and up-to-date webinars and courses, some of which are provided in collaboration with the EBMT. All things considered, the unforeseen changes and transitions forced upon us by the pandemic, resulted in an acceleration of the WMDA's activities to become more digital and thus more accessible to a much larger community than ever before.

One of the major outcomes of 2020 was that it was the first full year of reporting SEARs and SPEARs into the new software application. This tool has given us the ability to gain further insight into the occurrence of serious events and adverse effects in relation to stem cell donation by unrelated donors and blood stem cell collection/processing. In 2020, two rapid alerts were issued to advise our members of specific potential risks in the process of stem cell donation. Read more about the SEAR and SPEAR statistics in the annual SEAR/SPEAR report.

This year we intensified our collaborative relationship with our sister societies, FACT, ISCT, WBMT and EBMT, regarding education and experience. In August, the second edition of the EBMT/WMDA Transplant Coordinator Day was organised virtually. WMDA also participated in a joint session at ISCT together with the Cord Blood Association.

The WMDA is making steady progress; keeping up with the ever-changing world. During 2020, we worked on an infrastructure and governance framework to move towards a low-maintenance, secure and easy-to-access process for matching patients and donors, that registries can use to communicate with their international partners. The solution will be further developed in a way that both EMDIS and non-EMDIS registries will be able to communicate seamlessly. In 2021 the restructuring of pillar 1 should be finalized by including the EMDIS goes WMDA initiative.

On the third Saturday of September, the WMDA community organised World Marrow Donor Day for the sixth time. Many members used the digital materials designed by the WMDA to thank their donors and also to recruit new donors by raising awareness for patients worldwide in need of a stem cell transplant.

To investigate the role of the WMDA in the evolving field of stem cell therapy with the emerging cellular therapies that are being developed, the Cellular Therapy Task Force was created mid-2020. They aim to make substantial progress in 2021.

In 2020 we also elected new Board and Committee Members. In January 2021 we welcomed Ann O'Leary (chair Donor Registries WG), Valerie Stewart (chair-elect Donor Registries WG), Thilo Mengling (Board Member Promoting Donor Care), Chloe Anthias (chair Medical WG), Meghann Cody (chair-elect Medical WG), Susie Joron (chair Quality and Regulation WG), Joannis Mytilineos (chair-elect Quality and Regulation WG), Arun Prasath (member Standards Committee - representing pillar 2, Cord Blood), Matthew Prestegaard (member Standards Committee - representing pillar 1) and Yasser Almutairi (member Accreditation Committee - representing pillar 1).

After reading our WMDA Finance & Activities Report, you will realise that despite the COVID-19 pandemic and the associated challenges the WMDA faced, 2020 was a year of remarkable progress in our association. I'd like to express my deep gratitude to all who contributed to the major activities of WMDA, especially to our members around the world who are continuously providing stem cell products for patients in need of a transplant while keeping an eye on the donor. I also thank search coordinators, donor coordinators, medical directors, donor recruiters, cord blood bankers and registry directors for their resilience and for their hard work to save the lives of patients. We should and will not forget the health care providers and our patients and donors who tragically lost their lives due to COVID-19.

Finally, I thank you all for your continued commitment to WMDA, especially in this difficult time. Please take care of yourself and enjoy reading our 2020 WMDA Finance & Activities Report.

Sincerely,



JEFF SZER, AM MBBS FRACP
President, WMDA 2019-2020



2020 AT A GLANCE

VISION

Patients worldwide have equal access to high quality cells for transplantation from donors whose rights and safety are protected.

MISSION

To promote global collaboration and the sharing of best practices between its members for the benefit of stem cell donors and patients.

AIMS

Optimising 'Search, Match & Connect', supporting global development, promoting donor care and ensuring quality.

1045

WMDA passionate professionals

121

WMDA member organisations

35

WMDA accredited/qualified/certified organisations

Virtual meetings

| | |
|-----------------|-----|
| Meeting week(s) | 1 |
| Participants | 249 |

Education

| | |
|----|---|
| 42 | Educational webinars |
| 89 | Students completed an education programme |


Search & Match Service

30 756

Patients registered for a search

411

Registered users



STRATEGY

Foundation

Good Governance

The core principal of good governance is transparency. All members understand how and why decisions are made and how they can engage with and influence the decision-making process. Regular review of governance structures so they empower members and help achieve our aims & objectives. All decisions of the WMDA Board are visible for the WMDA members on WMDA Share.

Stable Resources

Our resources are stable and sustainable, so that we can deliver against our ambitious plans with tangible results. In 2020 our resources were stabilised by:

- EU operational grant to support WMDA's strategy.
- Support from our corporate partners: CareDX and Ontime Onboard Courier GmbH.
- Three new software developers that joined the WMDA staff.

Engaging Communication

The core principle of WMDA communication is based on sharing best practice amongst our diverse membership.

- Social Media: regularly review & consolidate our different channels with clear strategy for growth.
- Tools: provide useful data and information in various formats.
- Wiki: continuously improve and promote the Donor Medical Suitability Wiki as a valuable tool.
- Online Forums: always explore demand for online forums to share best practices and put these to good use accordingly.

STRATEGY

Pillars

OPTIMISING 'SEARCH, MATCH & CONNECT'

WMDA provides a global environment that facilitates access to the most suitable stem cell source.

- A global search platform that facilitates the best possible match between stem cell donors and transplant patients.
- User friendly with automation to improve and simplify searches and improved training to support users.
- Privacy and data security are safeguarded through the implementation of GRID and data agreements.

SUPPORTING GLOBAL DEVELOPMENT

WMDA supports members to develop and grow, so that more transplant patients find the most suitable stem cell source.

- The number and availability of stem cell donors increases in areas where transplantation activity is increasing: through data collection, sharing global trends and tailored support in developing areas.
- WMDA becomes a 'one-stop shop' for support and advice through expanded and improved online training.
- For patients that have no match in the Global Database, WMDA supports statistical analysis of the database for targeted donor recruitment and follows trends in development of cellular therapy.

PROMOTING DONOR CARE

WMDA ensures that the rights and safety of stem cell donors are promoted and protected.

- Informed donor care standards & practices through new and improved online SEAR/SPEAR reporting system for related & unrelated donors.
- Introduce professional training programme for those working with donors.
- Facilitate a donor suitability Wiki that is up to date and evidence based.

ENSURING QUALITY

WMDA promotes product quality and global collaboration through accreditation and standardisation.

- All organisations listing donors/cord blood units are making demonstrable progress towards accreditation through a tailored support package and peer support.
- WMDA & FACT accreditation are seen as the global Gold Standard through raising awareness amongst members, clinicians and authorities.
- WMDA sets an example by becoming ISO-certified.

ACTIVITIES

Pillar activities

OPTIMISING 'SEARCH, MATCH & CONNECT'

Search & Match Service

In 2020, WMDA:

- Provided a match-list for 30,756 patients who urgently needed a transplant.
- Gave access to 411 users who use Search Match for their daily work.
- Processed 35,782,124 GRID numbers for donors from 75 organisations from 52 countries and regions.
- Provided three search advices for difficult searches.
- Worked on alternative matching algorithms with support of DKMS (DE), NMDP-Be The Match (US), Anthony Nolan (UK).
- Migrated the WMDA digital infrastructure to the Azure cloud environment.
- In partnership with the EMDIS community, investigated a unified registry-to-registry communication solution.
- Enabled differential data upload to reduce time and effort spent creating and processing large files.
- Updated 35.1M (or 92%) of the donor records in WMDA on a monthly (16%), weekly (66.9%) or even daily (9.1%) basis by 63 organisations.
- Received 1,951,360 new donor records and 9,557 new CBU records onto the international database from 80 organisations in 53 countries and regions.

EMDIS

In 2020, EMDIS:


- A new member joined: the Turkish Stem Cell Coordination Center - TRKK Registry, growing the community to 44 donor registries.
- Finalised EMDIS Implementation Package 17 (IP17). WMDA member registries are no longer allowed to send D_ID (old donor ID). Only D_GRID or CB_ID is communicated.
- Approved RFCs 59, 63, 64, 65, 70, 71 and 72 (EMDIS 4.0).
- Created an executive summary with the findings and results of the tests and discussions during the EMDIS 4.0 pilot phase.
- Started the project 'EMDIS goes WMDA' in order to pool resources and to avoid building duplicate IT systems.
- Organised 2 virtual meetings:
 - on June the 22nd, in conjunction with the WMDA meeting;
 - on October the 27th.

EMDIS chair election

In July 2020 the following members were elected, and then approved by the membership as the new EMDIS chairs:

- Matti Korhonen (Finland) - User group chair
- Simona Pollichieni (Italy) - User group vice-chair
- David Steiner (Czech) - Technical group chair
- Jan Hoffman (Germany) - Technical group vice-chair.

Their term runs from October 2020 to December 2022.



Pillar activities

SUPPORTING GLOBAL DEVELOPMENT

Cord Blood

In 2020, WMDA:

- Further strengthened the strategic partnerships with the Foundation for the Accreditation of Cellular Therapy (FACT) and International Society Cell & Gene Therapy (ISCT) to better support and represent our cord blood bank members.
- Defined ready to ship cord blood units for listing in the 'Search & Match Service' Database.
- Facilitated listing of units from hybrid cord blood banks.
- Published a paper on key indicators:
 - [M. Jöris. \(2020\). Worldwide survey on key indicators for public cord blood banking technologies: By the World Marrow Donor Association Cord Blood Working Group. Stem Cells Journals. 10\(2\):222-229. <https://doi.org/10.1002/sctm.20-0246>.](#)
- Made public pages available on WMDA Share with cord blood banking specifics, both operational and technical for each cord blood bank.
- Launched a cord blood selection support service.
- Celebrated the third edition of World Cord Blood Day (WCBD) in November.

Education

In 2020, WMDA:

- Awarded 89 certificates to students completing the Search Coordinator Certificate Programme (SCCP) basic/advanced/ continuing courses:
 - 35 students completed basic level;
 - 20 students completed advanced level;
 - 26 students participated in the continuing education;
 - 8 students completed the donor coordinator training.
- Modernised the Education website, allowing students to study at their own pace.
- Organised special COVID-webinars to keep members up to date and connected.
- Held the second EBMT/WMDA Transplant Coordinator Day on 31 August (virtually) during the EBMT Annual Meeting.



Virtual meetings and congresses

In 2020, WMDA:

- Organised a Virtual Meeting Week in June with updates from the four Board Committee Pillars and the General Membership Meeting.
- A special End of the Year, Virtual Christmas Party.

Working Group Registries

In 2020, WMDA:

- Provided special COVID-pages on WMDA Share with updates per country and registry.
- Provided special COVID-pages for couriers, including travel vouchers and travel restriction/regulations per country.
- Organised a European waiver for couriers to enter EU member states without delay.


Annual statistics

In 2020, WMDA:

- Published annual statistics (2019) showing that the number of unrelated products provided are:
 - 3,924 HPC-Marrow
 - 16,406 HPC-Apheresis
 - 2,851 HPC-Cord

Global Trends Report 2020

Unrelated HPC Marrow, HPC Apheresis and HPC Cords shipped



Pillar activities

PROMOTING DONOR CARE

S(P)EAR

In 2020, WMDA:

- Received 474 reports from 32 organisations that reported a serious adverse event or reaction.
- Received 54 Covid-19 related reports, reviewed by the S(P)ear Committee.
- Introduced benchmarking of serious adverse events or reactions in relation to the reported stem cell collections worldwide.
- Presented the new SPEAR system at EBMT and APBMT.

Rapid alert(s)

In 2020, WMDA:

- Submitted two rapid alerts to the global community.

Guidelines and recommendations

In 2020, WMDA:

- Initiated the development of cryopreservation guidelines.
- Updated the WMDA Donor Medical Suitability Recommendations to include Hepatitis E.
- Published and updated the COVID-19 WMDA Donor Medical Suitability Recommendations criteria.

Publications

In 2020, WMDA:

- Presented at EBMT an abstract on [Serious Events and Adverse Reactions in relation to blood stem cell donation reported to WMDA in 2018](#).
- Published a paper on COVID-19 paper:
 - [J. Szer. \(2020\). The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone Marrow Transplantation. 55:2043-2044.
https://www.nature.com/articles/s41409-020-0873-x](#)
- Published a paper on the new S(P)EAR reporting system:
 - [M. Jöris. \(2020\). New global reporting system for serious \(product\) events and adverse reactions in hematopoietic stem cell donation and transplantation. Cell and Tissue Banking. 55
https://doi.org/10.1007/s10561-020-09863-y](#)

Cell Tissue Bank
<https://doi.org/10.1007/s10561-020-09861-y>



New global reporting system for serious (product) events and adverse reactions in hematopoietic stem cell donation and transplantation

Monique Jöris · Esther Pustjens · Thilo Mengling · Mirjam Fechter · Johanna Wiersum-Osselton · Arlinke Bokhorst · Lydia Foeken

Received: 29 April 2020 / Accepted: 26 August 2020
 © Springer Nature B.V. 2020

Abstract Annually more than 21,000 volunteer unrelated hematopoietic stem cell donations are performed worldwide for patients with life-threatening diseases such as acute leukaemia. Donor safety issues and donor protection is one of the top priorities for the international cooperation of unrelated hematopoietic stem cell donor registries represented by the World Marrow Donor Association (WMDA). With this new global reporting system for serious events and adverse reactions (S(P)EARS), the WMDA aims to become the global leading online platform for hematopoietic stem cell donor organizations to report their S(P)EARS from both unrelated and family donors. Software developer Cogapp developed the platform using a Knack environment based on requirements of experienced reporters and reviewers. On July 1st WMDA launched a robust online reporting system for S(P)EARS in order to provide accurate

information about potential risks to donors. The collected data about S(P)EARS occurring in donors will be analysed and used to provide statistics on the type of reports being submitted and to put in place best practices to mitigate such effects and occurrences. Via the annual S(P)EARS reports the results will be disseminated worldwide.

Keywords Serious (product) events and adverse reactions · Hematopoietic stem cell donation · Hematopoietic stem cell transplantation · Donor safety · Global collaboration · Reporting system

Introduction

World Marrow Donor Association's (WMDA) mission is to promote global collaboration and sharing of best practices between its members for the benefit of hematopoietic stem cell donors and patients. Reporting serious (product) events and adverse reactions (S(P)EARS) is part of that global collaboration. Members of WMDA include blood stem cell donor registries, cord blood banks and transplant centres.

Every year, more than 21,000 volunteer donors donate hematopoietic stem cells to a patient they do not know. To ensure the continued viability of the global system using volunteer donors, donor health and safety are of critical importance. Because more than half of the hematopoietic stem cells collected

M. Jöris (✉) · E. Pustjens · L. Foeken
 World Marrow Donor Association, Leiden, The Netherlands
 e-mail: Monique.joris@wmda.info

T. Mengling
 DKMS gencelntzige GmbH, Tübingen, Germany

M. Fechter
 Maxis, Leiden, The Netherlands

J. Wiersum-Osselton · A. Bokhorst
 TRIP Hemovigilance and Biovigilance Office, Leiden, The Netherlands

Published online: 09 September 2020



Bone Marrow Transplantation (2020) 55:2043–2044
<https://doi.org/10.1038/s41409-020-0873-x>



CORRESPONDENCE

The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage

Jeff Szer · Daniel Weisdorf¹ · Sergio Queiroz² · Lydia Foeken³ · Alejandro Madrigal⁴

Received: 5 March 2020 / Revised: 9 March 2020 / Accepted: 12 March 2020 / Published online: 23 March 2020
 © Springer Nature Limited 2020

To the Editor:

The provision of donors for life-saving hematopoietic stem cell transplants is coordinated through registries and facilitated by the World Marrow Donor Association (WMDA), which operates a global database to find the best stem cell source. The database contains 36,214,535 donors and 790,357 cord blood units from 98 different registries in 53 different countries [1].

The currently accelerating rate of COVID-19 infection and the responses of governments and facilities have the potential to impact and interfere with the timely provision of cells that must cross national borders. These cells are usually transported fresh after collection by individual or commercial couriers, while cord blood cells are transported while frozen though they still must be delivered promptly. In addition to transportation difficulties, possible exposures of the donor may affect the safety of the stem cell product. It is currently uncertain whether COVID-19 is transmissible parenterally, but it seems prudent to defer donors from endemic areas until suitable testing and observation time can ensure the safety of the product. This is particularly important if the donor is in a

country or region with a high rate of COVID-19 infection. Donation may be precluded by available health resources diverted to the infection, perceived risks to couriers and the consequent delays in exporting and importing the product.

A number of strategies have been proposed to assist in navigating through these rapidly evolving difficulties [2–4]. Timely communication to donors and patients with strategies to assist in the provision of alternative products and procedures to optimize cell collections may be required. Pre-emptive cryopreservation of products that are likely to be required at a time when transport may be further restricted is one option. This would allow complete infections testing to ensure that the product is not contaminated by infectious agents before use.

In addition, there may be a need to consider cord blood products more frequently as these products will have been collected and stored before the current infection became evident and cord blood units are always available immediately.

Policy and practice considerations in these unprecedented circumstances are mandatory and registries need to work with responsible authorities to minimize interference with necessary medical treatment and facilitate any available alternatives when required.

Organizations like WMDA could be vital to coordinate the urgent needs for cellular products. International cooperation and well-coordinated measures for donor provision will ensure that patients will be treated with the best product at the appropriate time.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ Jeff Szer
Jeff.Szer@mh.org.au

¹ Clinical Haematology at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia

² Blood and Marrow Transplant Program and Marston Cancer Center, University of Minnesota, Minneapolis, MN, USA

³ Frederic Duran I Jordà Center, Catalan Blood and Tissue Bank (BST), Barcelona, Spain

⁴ World Marrow Donor Association, Schipholweg 57, 2316 ZL, Leiden, The Netherlands

⁵ Anthony Nolan Research Institute Royal Free Hospital & UCL Medical School, London, UK

Pillar activities

Ensuring Quality

Projects

In 2020, WMDA:

- Updated WMDA Standards became effective on July 1, 2020.
- The standards cycle has been changed to 4 years. The next version of WMDA Standards will be in 2024.
- Improved WMDA Guidance with inputs from 10 standards with more RFI.
- Postponed one year all accreditation processes according to Board decision on the Accreditation Programme due to COVID-19.
- Started to develop a remote audit programme as an alternative to on-site inspections.
- Updated Application Templates in WMDA Share.
- Continued training of 52 reviewers using an electronic learning environment and weekly 15 minutes webinars.
- Updated reviewers' educational platform and modules.
- Reviewed and updated WMDA KPIs.
- Published the Registry to Registry problem management communication form.
- Made progress toward ISO 17065 for WMDA Accreditation Programme.

'WMDA Standards and accreditation are seen as the global standard by members, national and international authorities, and is reflected in regulatory frameworks'



WMDA Accreditation



WMDA Qualification



WMDA Certification

WMDA qualified and (re-)accredited organisations

| Country | Organisation | Accreditation status |
|---------|---|-------------------------|
| GB | Anthony Nolan | WMDA accredited |
| AU | Australian Bone Marrow Donor Registry | WMDA accredited |
| AT | Austrian Bone Marrow Donor Registry | WMDA qualified |
| CH | Blutspende SRK Schweiz AG | WMDA accredited |
| TW | Buddhist Tzu Chi Stem Cells Center - BTCSCC Hualien | WMDA accredited |
| CA | Canadian Blood Services Stem Cell Registry | WMDA accredited |
| CN | Chinese Marrow Donor Program | WMDA qualified |
| CY | Cyprus Bone Marrow Donor Registry | WMDA accredited |
| CZ | Czech National Marrow Donor Registry Plzeň | WMDA accredited |
| CZ | Czech Stem Cells Registry Prague (CSCR) | WMDA qualified |
| GB | DKMS United Kingdom | WMDA qualified |
| DK | Danish Stem Cell Donors - West | WMDA qualified |
| IL | Ezer Mizion Bone Marrow Donor Registry | WMDA accredited* |
| FI | Finnish Stem Cell Registry | WMDA qualified |
| FR | France Greffe de Moelle Registry - FGM | WMDA accredited |
| US | Gift of Life Marrow Registry | WMDA accredited |
| RU | HPC Registry (Samara) | WMDA qualified |
| CA | Hema-Quebec Stem Cell Donor Registry | WMDA accredited |
| IT | Italian Bone Marrow Donor Registry | WMDA accredited |
| JP | JMDP - Japan Marrow Donor Program | WMDA accredited |
| BE | Marrow Donor Program Registry Belgium | WMDA qualified |
| NL | Matchis Foundation | WMDA accredited |
| GB | NHS Blood and Transplant - BBMR | WMDA accredited* |
| US | NMDP-National Marrow Donor Program/Be The Match | WMDA accredited* |
| NZ | New Zealand Bone Marrow Donor Registry | WMDA accredited |
| NO | Norwegian Bone Marrow Donor Registry | WMDA accredited |
| BR | REDOME - Registro Nacional de Doadores Voluntarios de Medula Ossea | WMDA qualified |
| ES | Registro de Donantes de Médula Ósea (REDMO) | WMDA qualified |
| SG | Singapore BMDP | WMDA qualified |
| SG | Singapore Cord Blood Bank (CORD) | WMDA qualified |
| ZA | South African Bone Marrow Registry | WMDA accredited |
| TH | Thai National Stem Cell Donor Registry | WMDA qualified |
| SE | Tobias Registry | WMDA qualified |
| GB | Welsh Bone Marrow Donor Registry | WMDA accredited |
| DE | ZKRD - Zentrales Knochenmarkspender-Register Deutschland | WMDA accredited |

List of WMDA certified, qualified and accredited organisations. The bold-marked registries are WMDA Accredited. The blue-marked registries performed a WMDA Certification/ WMDA Qualification/WMDA (re-)Accreditation process in 2020.


*Accredited pending on-site visit: for registries that applied for Re-Accreditation and have had a positive desk review but could not complete the on-site visit in 2020 due to the outbreak.

WORLD MARROW DONOR DAY

SEPTEMBER 19, 2020



WORLDWIDE PARTICIPATION



World Marrow Donor Day was celebrated for the fifth time on 19th of September 2020. A special edition this year, because the COVID-19 pandemic hindered from organising big events.


Fortunately, the community was extremely creative in organising the 2020 edition of World Marrow Donor Day virtually. In addition to over 125 events reported on our event map in all parts of the world, we saw many online campaigns and video content for this virtual edition.

Virtual Global Donor Drive

With the slogan: 'Register online, save a life', organisations were encouraged to recruit donors online during World Marrow Donor Day. To facilitate this virtual global donor drive, a special landing page was set up on the World Marrow Donor Day website.

Global Thank You Donor video

To celebrate this virtual World Marrow Donor Day edition a special 'Thank You Donor' video was launched. Participants from all over the world sent in their contribution for this compilation video to send a massive thank you to all blood stem cell donors.



SOCIAL MEDIA IMPRESSIONS




WMDD 2020 prizes

Every year WMDA will hand out 3 prizes; the WMDD incentive prize, the WMDD originality prize and the WMDD grand prize, to 3 organisations that have celebrated WMDD in an exceptional way.

2020 winners were:

- Grand prize: National Registry of Romania
- Originality prize: REDOME Brazil
- Incentive prize: DATRI India

The winners presented their campaigns to the WMDA membership via a special webinar, which was held in the first quarter of 2021.



EU THIRD HEALTH PROGRAMME

In 2020, WMDA received an operational grant from the European Union to implement the EU Third Health Programme (2018-2021). This Health Programme is a funding instrument to support cooperation among EU countries and underpin and develop EU health activities. In addition, it outlines the strategy for ensuring good health and healthcare. The work programme of 2020 includes plans that will strengthen WMDA's capacity and capability in relation to communications, governance and resources. This will ensure required foundations are in place to support execution of an ambitious strategy that will deliver tangible benefit to WMDA and its member organisations.

Details of the different WMDA projects, outlining the objectives, activities and outcomes are made visible in annual Deliverables. These Deliverables cover all four pillars of WMDA.



Co-funded by
the Health Programme
of the European Union

We are pleased that the 11 Deliverables of the 2020 work programme were all approved by the European Commission:

- D1.1 Progress report on the accuracy, quality of data in the global database
- D1.2 Progress report on the implementation for a secure registry-to-registry communication system
- D2.1 Report on 2019 unrelated stem cell transplants
- D2.2 Report on import/export and registry operations within EU Member States
- D2.3 Defined education strategy for healthcare professionals in stem cell donation
- D2.4 Report on World Marrow Donor Day 2020
- D3.1 Online education materials for transplant centre physicians on SEAR reporting
- D3.2 Publication about the first year of the new software application and the importance of serious adverse events reporting
- D4.1 Webpage with materials of the workshop on data privacy standards
- D4.2 Progress report on the steps WMDA has taken to enhance the WMDA accreditation program including the strategy how to address organisations with low activity and how to certify the accreditation programme
- D4.3 Progress report on if it is feasible that WMDA will apply for ISO Certification

More information about these Deliverables for the EU Third Health Programme can be found in the EU Grants space on WMDA's Share.

[EU Grants on WMDA Share](#)

WMDA's 2021 work programme sets out activities and outcomes that will be delivered in pursuit of the overarching strategic aims set in the additional Framework Partnership between the WMDA and the European commission.



FINANCIAL REPORT

WMDA is an Association under Dutch law. Profits generated are invested in other activities to serve the community. The Board and Committee member contribute on a voluntary basis to the association's work. The WMDA office has its own employment arrangements. The employees in the WMDA office function according to various job profiles, which are linked to the remuneration policy.

Balance sheets as of December 31, 2020

(After result appropriation)

| ASSETS | 31 December 2020 | | 31 December 2019 | |
|--------------------------------------|------------------|------------------|------------------|------------------|
| | € | € | € | € |
| Fixed assets | | | | |
| <i>Intangible fixed assets</i> | | | | |
| IT development | - | - | 71.278 | 71.278 |
| <i>Tangible fixed assets</i> | | | | |
| Computers and Hardware | 18.340 | | 18.755 | |
| Inventory | 10.595 | | 13.490 | |
| | | 28.935 | | 32.245 |
| Current assets | | | | |
| <i>Receivables</i> | | | | |
| Accounts receivables | 17.404 | | 10.155 | |
| Taxes and premiums social insurance | 1.705 | | - | |
| Other receivables | 6.127 | | 6.127 | |
| Other prepayments and accrued income | 73.936 | | 40.798 | |
| | | 99.172 | | 57.080 |
| <i>Cash at bank and in hand</i> | | 1.793.429 | | 1.729.489 |
| Total assets | | <u>1.921.536</u> | | <u>1.890.092</u> |

Note on statements:

General Accounting Principles for the preparation of the financial statements: The financial statements are prepared according to the Netherlands Civil Code. A complete and detailed report can be requested at: mail@wmda.info.

Balance sheets as of December 31, 2020

(After result appropriation)

| | 31 December 2020 | | 31 December 2019 | |
|-------------------------------------|------------------|-----------|------------------|-----------|
| | € | € | € | € |
| LIABILITIES | | | | |
| Shareholders' equity | | | | |
| Other reserves | <u>1.423.056</u> | 1.423.056 | <u>1.457.173</u> | 1.457.173 |
| Current liabilities | | | | |
| Accounts payable | 160.003 | | 52.492 | |
| Taxes and premiums social insurance | 60.143 | | 93.275 | |
| Debts to the point of pensions | 10.695 | | - | |
| Other debts | 47.160 | | 24.614 | |
| Accrued liabilities | <u>220.479</u> | | <u>262.538</u> | |
| | | 498.480 | | 432.919 |

Note on statements:

General Accounting Principles for the preparation of the financial statements: The financial statements are prepared according to the Netherlands Civil Code. A complete and detailed report can be requested at: mail@wmda.info.

Overview of coverage and expenditures 2020

(*in euro -compilation report issue dated 2020)

| | 2020 | | 2019 | |
|---|---------|-----------------------|---------|---------------------|
| | € | € | € | € |
| Net turnover | | 1.656.938 | | 1.586.141 |
| Cost of sales | | 360.698 | | 405.972 |
| Gross operating result | | <u>1.296.240</u> | | <u>1.180.169</u> |
| Wages and salaries | 847.387 | | 776.376 | |
| Social insurances | 87.575 | | 84.430 | |
| Pension charges | 84.774 | | 81.271 | |
| Amortisation intangible fixed assets | 71.977 | | 36.033 | |
| Depreciation tangible fixed assets | 6.911 | | 5.278 | |
| Other personnel costs | 3.964 | | 45.710 | |
| Housing costs | 38.825 | | 38.702 | |
| Selling costs | 5.564 | | - | |
| Office costs | 118.198 | | 47.343 | |
| General costs | 63.848 | | 62.322 | |
| Total operating costs | | <u>1.329.023</u> | | <u>1.177.465</u> |
| Operating result | | <u>-32.783</u> | | <u>2.704</u> |
| Interest and similar expenditure | -1.332 | | -1.536 | |
| Total financial income and expenditure | | <u>-1.332</u> | | <u>-1.536</u> |
| Result before taxation | | <u>-34.115</u> | | <u>1.168</u> |
| Taxation | | - | | - |
| Result after taxation | | <u><u>-34.115</u></u> | | <u><u>1.168</u></u> |
| Reserve remaining | | -69.893 | | -5.128 |
| Reserve website / IT/ online collaboration | | - | | - |
| Reserve accreditation | | - | | - |
| Reserve continuity | | 44.935 | | 18.683 |
| Reserve relocation | | - | | -12.387 |
| Reserve NetCord | | -9.158 | | - |
| Reserve BMDW | | - | | - |
| | | <u><u>-34.116</u></u> | | <u><u>1.168</u></u> |

Note on statements:

General Accounting Principles for the preparation of the financial statements: The financial statements are prepared according to the Netherlands Civil Code. A complete and detailed report can be requested at: mail@wmda.info.

WORK PLAN AND BUDGET 2021

Based on WMDA's strategy, input was collected from WMDA members for the 2020 Work Plan & Budget.

Inputs were provided at two levels:

1. Ongoing projects and their proposed direction in 2021
2. New initiatives within existing programmes

For the new initiatives, WMDA has applied an operational grant from the EU. This operational grant covers additional investments that need to be done to execute the WMDA Strategy. The approved budget is summarized in the table below. The WMDA office is the central point for all activities of the WMDA

| | 2020 |
|-------------------------|-------------------|
| Income | Euro 1,797,397.00 |
| Expenses | Euro 1,867,28.00 |
| Estimated result | Euro -69,885.00 |

Note on statements:


General Accounting Principles for the preparation of the financial statements: The financial statements are prepared according to the Netherlands Civil Code. A complete and detailed report can be requested at: mail@wmda.info.

WMDA OFFICE HOURS

The WMDA office is the central point for all activities of the WMDA. In 2020, the WMDA office worked on multiple projects to assist the WMDA board committees and working groups. The WMDA office hours are specified in alignment with the pillar structure.

The specification of WMDA office hours 2020 can be found in the figure below.

Specification of WMDA office hours 2020



BOARD MEMBERS 2020



Jeff Szer, AU
Board member: President



Oliver Kürsteiner, CH
Board member: Treasurer



Henny Braund, UK
Board member: pillar 1 - Search, Match & Connect



Mike McCullough, US
Board member: pillar 1 - Search, Match & Connect



Dunia Jawdat, SA
Board member: pillar 2 - Global Development



Bronwen Shaw, US
Board member: pillar 3 - Donor Care



Nicoletta Sacchi, IT
Board member: pillar 4 - Quality



Carlheinz Mueller, DE
Board member: Past-President



Lydia Foeken, NL
Executive director
☎ +31 88 505 7900

Publisher: 2021 © WMDA

World Marrow Donor Association (WMDA)
Schipholweg 57, 1st floor,
2316 ZL Leiden,
The Netherlands

T: +31 88 505 7900
E: mail@wmda.info
W: www.wmda.info